comparemela.com
Home
Live Updates
CatalYm Commences Phase 2 Development of GDF-15-Targeting An
CatalYm Commences Phase 2 Development of GDF-15-Targeting An
CatalYm Commences Phase 2 Development of GDF-15-Targeting Antibody CTL-002 Following Successful Phase 1 Completion
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related Keywords
Spain ,
Germany ,
Switzerland ,
Catalym Gmb ,
Phil Lhuillier ,
Ignacio Melero Center ,
World Health Organization ,
International Nonproprietary Name ,
Trophic Communications ,
Differentiation Factor ,
Ignacio Melero ,
Advanced Medical Research ,
Principal Investigator ,
Eugen Leo ,
Chief Medical Officer ,
Phill Huillier ,
Growth Differentiation ,
Laura Mittmann ,
Catalym Gmbh ,
Business Wire ,
Business ,
Health ,
Tumors ,